Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

No statistically significant change in MADRS total score was observed with solriamfetol vs placebo in the overall study population. Topline results were announced from a phase 3 trial evaluating ...

Compared with placebo, pitolisant 20 and 40 mg had a greater treatment response for residual excessive daytime sleepiness in patients with OSA treated with CPAP. Pitolisant reduces residual excessive ...

Compared with placebo, pitolisant 20 and 40 mg had a greater treatment response for residual excessive daytime sleepiness in patients with OSA treated with CPAP. Pitolisant reduces residual ...

Idiopathic hypersomnia is a neurological sleep disorder characterised by excessive daytime sleepiness despite getting a full ...

Observers say married couples may experience greater levels of financial and emotional stress that hasten the onset of ...

Please provide your email address to receive an email when new articles are posted on . Using baseline scores as reference points, three measures of cognitive function improved more when patients ...

In a recent Managed Healthcare Executive K-Cast video series, R. Robert Auger, M.D., a psychiatrist and sleep specialist at the Mayo Clinic in Rochester, Minnesota, spoke about the diagnosis and ...

Share on Pinterest Excessive sleepiness as we grow older may be a warning sign of dementia, new research says. Image credit: francesco_de_napoli/Getty Images. At least 55 million people are living ...